Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors

Background Polypharmacy in older adults with cancer receiving chemotherapy leads to increased risks of drug interactions, translating in potential hazardous health outcomes.

This study aims to assess the prevalence of polypharmacy, drug–drug interactions (DDIs), and severe-drug interactions (SDIs) in older patients with cancer.

Antineoplastic agents (ANAs) involvement and possible risk contexts (comorbidities with cardiac risk, and high-risk medications) were also analysed.

Methods Observational study with older adults (≥ 65 years) diagnosed with cancer, who were treated with antineoplastic agents (ANAs); it was conducted in three hospitals from the north of Portugal.

Data collection was obtained using self-reports and medical records.

DDIs were identified and classified using Micromedex® software.

Descriptive and association analyze statistics were performed.

Statistical hypothesis tests with p value less than 0.05 were considered significant.

All statistical procedures and analysis were performed with R version 4.1.3.

Results We enrolled 552 patients.

Polypharmacy prevalence was 88.40%; 76.45% and 56.16% of the patients presented with DDIs and SDIs, respectively.

SDIs with ANAs were found in 21.20% of the patients.

High-risk medications were associated with a higher risk of polypharmacy, DDIs, and SDIs.

Polypharmacy and DDIs were higher in patients with hypertension or diabetes.

SDIs were higher in patients with diabetes.

Conclusion Polypharmacy, potential DDIs and SDIs were highly prevalent in older adults with cancer.

A careful review of the medication administered is necessary to decrease it.

These findings warrant further research to optimize medication in this population and decrease problems related to medication, which may lead to emergency room visits and hospitalisations, compromising patient safety and/or ongoing treatments.